Establishing Quality of Life in Southern Taiwan COPD Patients Using Long-Acting Bronchodilator

References

• Portegies MLP, Lahousse L, Joos GF, et al. Chronic obstructive pulmonary disease and the risk of stroke. The Rotterdam Study. Am J Respir Crit Care Med. 2015;193(3):251–258. doi:10.1164/rccm.201505-0962OC
   Web of Science ®Google Scholar
• World Health Organization. Projections of mortality and causes of death, 2016 to 2060. Available from: https://www.who.int/healthinfo/global_burden_disease/projections/en/. Accessed March 23, 2022.
   Google Scholar
• Cheng SL, Chan MC, Wang CC, et al. COPD in Taiwan: a national epidemiology survey. Int J Chron Obstruct Pulmon Dis. 2015;10:2459–2467. doi:10.2147/copd.S89672
   PubMed Web of Science ®Google Scholar
• Vogelmeier C, Anzueto A, Barnes P. Global strategy for diagnosis, management and prevention of COPD 2021 update. Available from: https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdf. Accessed August 24, 2021.
   Google Scholar
• Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease NHLBI/WHO workshop report. Review. Rev Port Pneumol. 2001;7(6):621–667.
   Google Scholar
• Gary TF, Make B. Stable COPD: initial pharmacologic management. UptoDate. 2019.
   Google Scholar
• Moretz C, Sharpsten L, Bengtson LG, et al. Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study. Int J Chron Obstruct Pulmon Dis. 2019;14:1721–1737. doi:10.2147/COPD.S204649
   PubMed Web of Science ®Google Scholar
• Frampton JE. Qva149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease. Review. Drugs. 2014;74(4):465–488. doi:10.1007/s40265-014-0194-8
   PubMed Web of Science ®Google Scholar
• Chen YF, Cheng YC, Chou CH, Chen CY, Yu CJ. Major comorbidities lead to the risk of adverse cardiovascular events in chronic obstructive pulmonary disease patients using inhaled long-acting bronchodilators: a case-control study. BMC Pulm Med. 2019;19(1):233. doi:10.1186/s12890-019-0999-z
   PubMed Web of Science ®Google Scholar
• Chuang HY, Chang H, Fang YY, Guo SE. The effects of threshold inspiratory muscle training in patients with chronic obstructive pulmonary (COPD) disease: a randomized experimental study. J Clin Nurs. 2017;26:4830–4838. doi:10.1111/jocn.13841
   PubMed Web of Science ®Google Scholar
• Lan CC, Yang MC, Huang HC, et al. Serial changes in exercise capacity, quality of life and cardiopulmonary responses after pulmonary rehabilitation in patients with chronic obstructive pulmonary disease. Heart Lung. 2018;47(5):477–484. doi:10.1016/j.hrtlng.2018.06.006
   PubMed Web of Science ®Google Scholar
• Liou HL, Huang YT, Lai ZY, et al. Improving self-care efficacy and quality of life with a self-management program among patients with chronic obstructive pulmonary disease: a quasi-experimental study. Nurs Health Sci. 2020;22(3):629–638. doi:10.1111/nhs.12703
   PubMed Web of Science ®Google Scholar
• Engström CP, Persson LO, Larsson S, Sullivan M. Health-related quality of life in COPD: why both disease-specific and generic measures should be used. Eur Respir J. 2001;18(1):69–76. doi:10.1183/09031936.01.00044901
   PubMed Web of Science ®Google Scholar
• Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care. 1989;27(3 Suppl):S217–32. doi:10.1097/00005650-198903001-00018
   PubMed Web of Science ®Google Scholar
• Yao G, Chung CW, Yu CF, Wang JD. Development and verification of validity and reliability of the Whoqol-Bref Taiwan version. J Formos Med Assoc. 2002;101(5):342–351.
   PubMed Web of Science ®Google Scholar
• Lin H-W, Li C-I, Lin F-J, et al. Valuation of the Eq-5d-5l in Taiwan. PLoS One. 2018;13(12):e0209344. doi:10.1371/journal.pone.0209344
   PubMed Web of Science ®Google Scholar
• Wang KY, Chiang CH, Maa S, Shau Y-W, Tarn YH. Psychometric assessment of the Chinese language version of the St. George’s respiratory questionnaire in Taiwanese patients with bronchial asthma. J Formosan Med Assoc. 2001;100:455–460.
   PubMed Web of Science ®Google Scholar
• Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD assessment test. Eur Respir J. 2009;34(3):648–654. doi:10.1183/09031936.00102509
   PubMed Web of Science ®Google Scholar
• Ghobadi H, Ahari SS, Kameli A, Lari SM. The relationship between COPD assessment test (cat) scores and severity of airflow obstruction in stable COPD patients. Tanaffos. 2012;11(2):22–26.
   PubMedGoogle Scholar
• Air quality monitoring data. Available from: https://data.epa.gov.tw/dataset?q=%E7%A9%BA%E6%B0%A3%E5%93%81%E8%B3%AA. Accessed March 23, 2022.
   Google Scholar
• Biswas M, Chattopadhyay K. Relationship between health-related quality of life and respiratory health status among coal-based sponge iron plant workers in Barjora, India. J Public Health (Bangkok). 2018;26(3):355–359. doi:10.1007/s10389-017-0861-9
   Web of Science ®Google Scholar
• Yu ST, Chang HY, Yao KP, Lin YH, Hurng B-S. Validity of Eq-5d in general population of Taiwan: results of the 2009 national health interview and drug abuse survey of Taiwan. Qual Life Res. 2015;24(10):2541–2548. doi:10.1007/s11136-015-0978-7
   PubMed Web of Science ®Google Scholar
• Criner RN, Labaki WW, Regan EA, et al. Mortality and exacerbations by global initiative for chronic obstructive lung disease groups ABCD: 2011 versus 2017 in the Copdgene® cohort. Chronic Obstruct Pulmon Dis. 2019;6(1):64–73. doi:10.15326/jcopdf.6.1.2018.0130
   PubMed Web of Science ®Google Scholar
• Bhatta L, Leivseth L, Mai X-M, et al. Gold classifications, COPD hospitalization, and all-cause mortality in chronic obstructive pulmonary disease: the hunt study. Int J Chron Obstruct Pulmon Dis. 2020;15:225–233. doi:10.2147/COPD.S228958
   PubMed Web of Science ®Google Scholar
• Hsieh MJ, Huang SY, Yang TM, et al. The impact of 2011 and 2017 global initiative for chronic obstructive pulmonary disease (gold) guidelines on allocation and pharmacological management of patients with COPD in Taiwan: Taiwan obstructive lung disease (told) study. Int J Chron Obstruct Pulmon Dis. 2018;13:2949–2959. doi:10.2147/copd.S176065
   PubMed Web of Science ®Google Scholar
• Lutter JI, Jörres RA, Trudzinski FC, et al. Treatment of COPD groups gold A and B with inhaled corticosteroids in the cosyconet cohort - determinants and consequences. Int J Chron Obstruct Pulmon Dis. 2021;16:987–998. doi:10.2147/copd.s304532
   PubMed Web of Science ®Google Scholar
• Cataldo D, Derom E, Liistro G, et al. Overuse of inhaled corticosteroids in COPD: five questions for withdrawal in daily practice. Int J Chron Obstruct Pulmon Dis. 2018;13:2089–2099. doi:10.2147/COPD.S164259
   PubMed Web of Science ®Google Scholar
• Singh D, Jones PW, Bateman ED, et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (Acliform-COPD): a multicentre, randomised study. BMC Pulm Med. 2014;14:178. doi:10.1186/1471-2466-14-178
   PubMed Web of Science ®Google Scholar
• Feldman G, Maltais F, Khindri S, et al. A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 Μg compared with tiotropium 18 Μg in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:719–730. doi:10.2147/COPD.S102494
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–1554. doi:10.1056/NEJMoa0805800
   PubMed Web of Science ®Google Scholar
• Dahl R, Chung KF, Buhl R, et al. Efficacy of a new once-daily long-acting inhaled Beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010;65(6):473–479. doi:10.1136/thx.2009.125435
   PubMed Web of Science ®Google Scholar
• Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A. Efficacy and safety of once-daily umeclidinium/vilanterol 62. 5/25mcg in COPD. Respir Med. 2013;107(10):1538–1546. doi:10.1016/j.rmed.2013.06.001
   PubMed Web of Science ®Google Scholar
• Huijsmans RJ, de Haan A, ten Hacken NN, Straver RVM, Van’t Hul AJ. The clinical utility of the gold classification of COPD disease severity in pulmonary rehabilitation. Respir Med. 2008;102(1):162–171. doi:10.1016/j.rmed.2007.07.008
   PubMed Web of Science ®Google Scholar
• Kang J, Lee JS, Lee SW, Lee JB, Oh Y-M. Dual versus monotherapy with bronchodilators in gold group B COPD patients according to baseline Fev1 level: a patient-level pooled analysis of phase-3 randomized clinical trials. Respir Res. 2021;22(1):55. doi:10.1186/s12931-021-01648-5
   PubMed Web of Science ®Google Scholar
• Sciriha A, Lungaro-Mifsud S, Scerri J, Magro R, Camilleri L, Montefort S. Health status of COPD patients undergoing pulmonary rehabilitation: a comparative responsiveness of the Cat and Sgrq. Chron Respir Dis. 2017;14(4):352–359. doi:10.1177/1479972317694622
   PubMed Web of Science ®Google Scholar
• Weatherall M, Marsh S, Shirtcliffe P, Williams M, Travers J, Beasley R. Quality of life measured by the St George’s respiratory questionnaire and spirometry. Eur Respir J. 2009;33(5):1025. doi:10.1183/09031936.00116808
   PubMed Web of Science ®Google Scholar
• Starkie HJ, Briggs AH, Chambers MG, Jones P. Predicting Eq-5d values using the Sgrq. Value Health. 2011;14(2):354–360. doi:10.1016/j.jval.2010.09.011
   PubMed Web of Science ®Google Scholar
• Brandl M, Böhmer MM, Brandstetter S, et al. Factors associated with generic health-related quality of life (HRQOL) in patients with chronic obstructive pulmonary disease (COPD): a cross-sectional study. J Thorac Dis. 2018;10(2):766–775. doi:10.21037/jtd.2018.01.122
   PubMed Web of Science ®Google Scholar
• Ringbaek T, Martinez G, Lange P. A comparison of the assessment of quality of life with Cat, Ccq, and Sgrq in COPD patients participating in pulmonary rehabilitation. Copd. 2012;9(1):12–15. doi:10.3109/15412555.2011.630248
   PubMedGoogle Scholar
• Luttmann-Gibson H, Dockery DW, Speizer FE. Short-term and long-term effects of air pollution on lung function. Epidemiology. 2004;15(4):S42. doi:10.1097/00001648-200407000-00096
   Web of Science ®Google Scholar